• VIEW CLINICAL TRIALS
  • MEDIA CENTER
  • CONTACT US
Eisai U.S. logo Search icon Close icon
  • WHO WE ARE
      • hhc Mission
      • Corporate Responsibility
      • Locations
      • Leadership
      • Awards and Recognition
      • Our History
      • Collaborations
  • OUR SCIENCE
      • Global Pipeline
      • Disease Areas
      • Clinical Trials
      • G2D2
  • OUR MEDICINES
      • Our Products
      • Manufacturing
      • Eisai Medical Information
      • Pharmacy Trade Relations
  • OUR PATIENT FOCUS
      • Community Involvement
      • Magnolia Patient Support Programs
      • Eisai USA Foundation
      • Eisai Grants Programs
  • CAREERS
  • Search icon Close icon
  • VIEW CLINICAL TRIALS
  • MEDIA CENTER
  • CONTACT US
  1. Home
    >
  2. Media Center
    >
Text saying Media Center, our online resource featuring the latest news about our company over a pixelated background graphic

Media Center

Our online resource featuring the latest news about our company.

graphics

Recent News, Blogs and Articles

May 20, 2025

icon Press Release

Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025

arrow icon

May 15, 2025

icon Blog

Leadership Perspective: Innovation and Cooperation in Alzheimer’s Disease

arrow icon

April 21, 2025

icon Blog

Collaboration between Medical Affairs and Clinical Teams to Advance Patient Care

arrow icon

April 16, 2025

icon Press Release

Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

arrow icon

Explore All Articles

arrow icon

Explore All Blogs

arrow icon

Explore All Press Releases

arrow icon
graphics

Media Resources

Corporate Fact Sheet

Learn more about Eisai Inc.

icon

Exton Fact Sheet

Learn more about our Exton, PA campus

icon

Digital Asset Library

Find logos, images, videos

icon
graphics

Contact Information

For media inquiries, please contact:

Corporate

profile icon

Chris Vancheri
Associate Director, Corporate
Communications

phone icon

551-305-0050

551-305-0050
email icon Christopher_Vancheri@eisai.com

Neurology

profile icon

Libby Holman
Senior Director, Product
Communications

phone icon

201-753-1945

201-753-1945
email icon Libby_Holman@eisai.com

Oncology

profile icon

Michele Randazzo
Senior Director, Product
Communications

phone icon

201-248-2228

201-248-2228
email icon Michele_Randazzo@eisai.com

Investors

For current investors or those interested in becoming investors, please click below to be connected with the global Eisai Investor page.

investor info
investor info

Social Media

Stay up to date on everything Eisai.

Twitter logo Linkedin logo
WHO WE ARE
  • hhc Mission
  • Our Locations
  • Corporate Responsibility   
  • Leadership
  • Awards and Recognitions  
  • Our History
  • Collaboration
OUR SCIENCE
  • Global Pipeline
  • Disease Areas
  • Clinical Trials
  • G2D2
OUR MEDICINES
  • Our Products
  • Manufacturing
  • Eisai Medical Information
  • Pharmacy Trade Relations
OUR PATIENT FOCUS
  • Community Involvement   
  • Magnolia Patient Support
  • Eisai USA Foundation
  • Eisai Grants Programs
CAREERS AT EISAI
  • Search Job Openings
  • Career Areas
  • Life at Eisai
  • Career Growth & Development
  • Compensation &
    Benefits
  • Diversity, Equity & Inclusion
MEDIA CENTER CONTACT US VIEW CLINICAL TRIALS
Linkedin logo Twitter logo
Site Map Cookie Preferences US Privacy Policy Your Choices and Rights California Privacy Supplement
Consumer Health Data Privacy Supplement Legal Notices & Industry Practices EU/UK Privacy Policy
Eisai Co. Ltd. External link icon Eisai CA External link icon Eisai EU External link icon

This is the website of Eisai Inc., a US company. This site is intended for US residents only. The health information contained
herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All
decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

US2639  |  Copyright ©Eisai Inc. 2024. All Rights Reserved.

YOU’RE ABOUT TO LEAVE US.EISAI.COM

By clicking on the CONTINUE button you will be leaving the Eisai Inc. U.S. website. Eisai assumes no responsibility for, and exercises no control over, the accuracy or information on this external website.